Arovella appoints former CSL CSO Dr Andrew Nash as Non-executive Director
MELBOURNE, AUSTRALIA 12 November 2025: Arovella Therapeutics Ltd (ASX: ALA) is pleased to announce the appointment of Dr Andrew Nash as Non-Executive Director, effective 12 November 2025.
Dr Nash has over 35 years of practical drug development experience and executive leadership in the biotech and pharmaceutical sector, most recently with Australia’s largest and most successful pharmaceutical company, CSL. Dr Nash initially trained as an academic scientist after completing his PhD in Immunology. He then joined Zenyth (formerly Amrad Corp), where he advanced to become Chief Scientific Officer (CSO), and ultimately CEO before it was sold to CSL in 2006. Dr Nash was appointed CSO of CSL in 2020 and remained in that position until his retirement in March 2025.
Dr Nash has had a distinguished career, being elected as a Fellow of the Academy of Technological Sciences and Engineering in 2021, and as a Fellow of the Australian Academy of Science in 2025. He was the inaugural Chair of Jumar Bioincubator and is currently a Board Director at the Burnet Institute, the Garvan Institute of Medical Research, Brandon BioCatalyst and Denteric, a vaccine-focused biotechnology company in Melbourne.
Arovella’s CEO and MD, Dr Michael Baker, remarked: “I have had the pleasure of getting to know Andrew since we established Arovella’s first office in the Jumar Bioincubator in 2023. We are delighted that someone with Andrew’s track record, with relevant experience at a senior level across all facets of drug development and commercialisation, has agreed to join Arovella’s Board of Directors as the Company transitions to a clinical-stage company with a promising pipeline.”
Dr Andrew Nash commented: “I am delighted to join Arovella’s Board of Directors. I see great potential in Arovella’s approach to tackling blood cancers and solid tumours. I have had the pleasure of meeting several of the team members, who are equally impressive as the technology being developed. This is clearly an exciting time for the company, as it looks to take its first product into clinical trials. In addition, the pipeline is developing well, and the balance sheet is strong. I look forward to adding value on multiple fronts.”
The intention is for Dr Nash to transition from the role of Non-executive Director to Non-executive Chairman of the Board, and the Company looks forward to providing an update in due course.